* TherapeuticsMD Inc TXMD.OQ TXMD.O is expected to show
a rise
in quarterly revenue when it reports results on March 10.
* The Boca Raton Florida-based company is expected to
report a
30.2% increase in revenue to $29.39 million from $22.58 million
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for TherapeuticsMD Inc
is for
a loss of 8 cents per share. For the same quarter last year, the
company reported a loss of 15 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for
TherapeuticsMD
Inc is $5, about 94% above its last closing price
of $0.30.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2021 -0.10 -0.10 -0.11 Missed -10
Jun. 30 2021 -0.11 -0.11 -0.11 Met 0
Mar. 31 2021 -0.12 -0.12 -0.11 Beat 5.2
Dec. 31 2020 -0.11 -0.10 -0.15 Missed -42.9
Sep. -0.14 -0.14 -0.12 Beat 12.2
30 2020
Jun. 30 2020 -0.17 -0.17 -0.19 Missed -10.7
Mar. 31 2020 -0.19 -0.19 -0.21 Missed -12
Dec. 31 2019 -0.19 -0.19 -0.19 Met -1.5
This summary was machine generated March 8 at 17:02 GMT. All
figures in US dollars unless otherwise stated